| Catalog: | C-FC-3314A |
| Product Type: | FCM Antibody |
| Size: | 50 µL/100 µL/200 µL |
| Reactivity: | Human |
| Specificity: | Human ICOS ligand |
| Analysis mode: | FCM |
| Host: | Mouse |
| Clonality: | Monoclonal |
| Isotype: | IgG1 |
| Alternate names: | inducible T-cell co-stimulator ligand |
| Form: | Liquid |
| Shipping: | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage: | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
| Purification method: | Protein A |
| Conjugation: | Unconjugated |
| Immunogen: | Recombinant Human ICOS Ligand / B7-H2 Protein |
| Buffer: | 0.2 μm filtered solution in PBS |
| Application: | Cancer Drug Targets |
Inducible co-stimulator ligand (ICOSL), also known as B7-H2, is a member of the B7 family of co-stimulatory molecules related to B7-1 and B7-2. It is a transmembrane glycoprotein with extracellular IgV and IgC domains and binds to ICOS on activated T cells, thus delivers a positive costimulatory signal for optimal T cell function. The structural features of ICOSL are crucial for its costimulatory function. The present study shows that ICOSL displays a marked oligomerization potential, resembling more like B7-1 than B7-2. B7-H2-dependent signaling may play an active role in a proliferative response rather than in cytokine and chemokine production. The CD28/B7 and ICOS/B7-H2 pathways are both critical for costimulating T cell immune responses. Deficiency in either pathway results in defective T cell activation, cytokine production, and germinal center formation.
Copyright © 2025 Creative Biogene. All rights reserved.